| Not Yet Recruiting | A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis NCT06900192 | Stanford University | Phase 1 |
| Recruiting | Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland) NCT06526364 | University Hospital, Basel, Switzerland | — |
| Completed | PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF NCT06683612 | Contineum Therapeutics | Phase 1 |
| Active Not Recruiting | KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive NCT06384976 | Kyverna Therapeutics | Phase 2 |
| Recruiting | A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Prog NCT06138132 | Stanford University | Phase 1 |
| Completed | The Effects of In-phase Bilateral Exercise in People with Progressive Multiple Sclerosis NCT06436131 | Cyprus University of Technology | N/A |
| Recruiting | Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy NCT05359653 | University of California, San Francisco | Phase 1 / Phase 2 |
| Completed | An Observational Biomarker Study in Multiple Sclerosis (MS) Patients NCT05663853 | LAPIX Therapeutics Inc. | — |
| Unknown | MUSCLE - Nordic Walking in MUltiple SCLErosis NCT05385731 | Leonardo A. Peyré-Tartaruga | N/A |
| Unknown | Exercise Effects in Multiple Sclerosis NCT05496881 | University of Regina | N/A |
| Active Not Recruiting | Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis NCT05122559 | Emmanuelle Waubant, MD PhD | Phase 2 |
| Recruiting | MS-ResearchBiomarkerS NCT05204459 | Cedars-Sinai Medical Center | — |
| Completed | Motor Asymmetry in Progressive Multiple Sclerosis Patients NCT04918225 | Rennes University Hospital | — |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants Wi NCT04544449 | Hoffmann-La Roche | Phase 3 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Scleros NCT04035005 | Hoffmann-La Roche | Phase 3 |
| Completed | Improving Cognition in People With Progressive Multiple Sclerosis Using Aerobic Exercise and Cognitive Rehabil NCT03679468 | Sunnybrook Health Sciences Centre | N/A |
| Active Not Recruiting | Cognition Evolution and MRI Markers in PPMS Patients on 2 Years NCT03455582 | University Hospital, Bordeaux | N/A |
| Completed | Follow-up Study of the Effectiveness of Virtual Reality Therapy in MS Patients NCT04550650 | Somogy Megyei Kaposi Mór Teaching Hospital | N/A |
| Completed | The Effect of Neurorehabilitation Therapy on Postural Control, Mobility and Quality of Life in Multiple Sclero NCT03424538 | Somogy Megyei Kaposi Mór Teaching Hospital | N/A |
| Completed | Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis NCT02988401 | Johns Hopkins University | Phase 1 / Phase 2 |
| Completed | Hydroxychloroquine in Primary Progressive Multiple Sclerosis NCT02913157 | University of Calgary | Phase 2 |
| Completed | Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Mult NCT02688985 | Genentech, Inc. | Phase 3 |
| Completed | Open-label Study of Liothyronine in MS NCT02506751 | Johns Hopkins University | Phase 1 |
| Completed | Aerobic Exercises for Multiple Sclerosis NCT04545372 | South Valley University | N/A |
| Completed | Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis NCT01982942 | MediciNova | Phase 2 |
| Completed | A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multi NCT01917019 | Biogen | Phase 3 |
| Completed | Imaging of Intracerebral Inflammation in MS NCT02305264 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis NCT01433497 | AB Science | Phase 3 |
| Completed | A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis NCT01194570 | Hoffmann-La Roche | Phase 3 |